RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) based on preliminary clinical ...
KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--#CTAD2025--Cognito Therapeutics, a clinical-stage medical device company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, today ...
Abstract: Industry 5.0 is a emerging transformative model that aims to develop a hyperconnected, automated, and data-driven industrial ecosystem. This digital transformation will boost productivity ...
A federal appeals court has upheld a penalty of nearly $1 million against President Donald Trump and attorney Alina Habba, concluding they committed “sanctionable conduct” by filing a frivolous ...
BOSTON--(BUSINESS WIRE)--Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced that its first results from the ongoing inMMyCAR study, a ...
Abstract: Impaired renal function poses a risk across all age groups. Because of the global shortage of nephrologists, the growing public health concern over renal failure, and technological ...
Precise Bio, a clinical-stage regenerative medicine company pioneering bio-printed tissues and organs with an initial focus on ophthalmology, has successfully treated the first patient with PB-001, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback